Product News and Recalls

Journalist questions new Yaz, Beyaz, and Yasmin warnings

In a recent entry for “re:Cycling,” the blog of the Society for Menstrual Cycle Research, journalist Holly Grigg-Spall questions whether the U.S. Food and Drug Administration went far enough in its new labeling requirements for the Yasmin line of birth control pills.

Grigg-Spall points out that the new labels mention the results of “conflicting” studies, most of which concluded that the pills in question cause a significant increase ...

continue reading...

Doctor: No advantage to dangerous implant

In testimony before the U.S. Food and Drug Administration, Dr. Michael Carome called for a ban on all vaginal mesh products, on the grounds that they have no advantages over other forms of treatment, yet cause a host of severe health problems.

Mesh implants are used to treat urinary incontinence and pelvic organ prolapse – a condition that results when weakened muscles provide inadequate support for internal ...

continue reading...

Office workers at particular risk of blood clots

According to a study from New Zealand, workers who spend long periods of time immobile at their desks could be putting themselves at risk for potentially fatal blood clots.

A BBC report says researchers found that a third of patients hospitalized with deep vein thrombosis were office workers who spent extended periods of time at a computer.

The report says the condition is commonly called “economy class syndrome,” because passengers sitting in ...

continue reading...

Report examines Zoloft use during pregnancy

According to an ABC News report, relatively stable women suffering from depression may want to consider going off their antidepressants for the first trimester of a pregnancy, although they should keep in mind that it will take four-to-six weeks for the drug effect to wear off and that the medications should be resumed at the first sign of a relapse.

The report also makes it clear that going ...

continue reading...

J&J reports profit increase, despite troubles

Johnson & Johnson reports that its first-quarter profits increased by 12.5 percent, Bloomberg reports. That increase came despite the company’s problems with nearly 30 recalls for a number of nonprescription and prescription medicines, as well as medical devices.

That 12.5-percent increase came about primarily because of lower spending on research, sales and administration and a boost from selling rights to a drug, the report said.

According to the report, Johnson & ...

continue reading...

Activist questioned corporate-funded Yaz studies

A former board member of Our Bodies, Ourselves, a nonprofit women’s advocacy group, publicly questioned why industry-funded studies were the only ones that appeared to show no higher risk of blood clots from the Yasmin line of contraceptives, compared to other types of birth control pills on the market.

An entry in the organization’s blog mentions testimony that Pamela Bridgewater presented at a U.S. Food and Drug Administration panel’s December ...

continue reading...
Page 355 of 386 «...330340350353354355356357...»